Assessment of rational use of medicines for chronic non-communicable diseases: A cross-sectional design in a public access clinic in Jamaica

Donna-Marie Wynter-Adams1,2, Peta-Gaye Thomas-Brown2, Marcia Williams2, Lisa Bromfield2 and Janice Bunting-Clarke2

Abstract

Background: Rational use of medicines (RUM) offers a cost-saving strategy to maximize therapeutic outcomes. The aims of this study were to assess RUM for chronic non-communicable diseases (NCDs) using the World Health Organization’s (WHO) prescribing indicators in a public access facility and to evaluate the alignment of the use of drugs with therapeutic recommendations/guidelines.

Design and methods: In this retrospective cross-sectional study, prescriptions of adult patients containing at least one drug for chronic NCDs, filled between January and July 2019 were reviewed using the WHO prescribing indicators for RUM. Data were analyzed and expressed as descriptive statistics. Associations were determined using chi-square tests, correlations using Pearson’s correlation and medians compared using Mann-Whitney U test. For all analyses, significance was determined at $p < 0.05$.

Results: Of the 571 prescriptions reviewed, most were for female, elderly patients with mean age of 69 years, predominantly with hypertension and/or diabetes. Polypharmacy was noted for 53.6% of prescriptions, primarily in elderly patients ($p < 0.001$), with the median number of five drugs prescribed and three dispensed. Of the drugs prescribed, 76.6% used generic prescribing, 63.3% were dispensed as written and 3.9% were antibiotics prescribed mainly for asthmatic patients ($\chi^2 = 74.9, p < 0.001$). Drugs prescribed for NCDs were aligned to therapeutic guidelines, but a significantly higher proportion of diabetes medications, (metformin and gliclazide), and cardiovascular medications (enalapril and losartan), were not dispensed as written ($\chi^2 = 40.0, p = 0.007$).

Conclusion: This research indicates that there is positive alignment with recommended therapeutic guidelines, however, based on WHO prescribing factors, strategies to improve RUM in this setting are highly recommended.

Keywords
Rational use of medicine, WHO prescribing indicators, non-communicable diseases, Jamaica

Introduction

Rational use of medicines (RUM) is the efficient use of health resources, with the selection of appropriate medications based on diagnosis or clinical needs, and administration at the right dose and frequency in a cost-effective manner.1 This can be summarized as the ABCs of RUM, which are: Appropriate diagnosis, based on sound therapeutic guidelines, Best drug indicated for the diagnosis using efficacy, safety, and cost data, Candidate is suited to receive the selected drug, with no clear contraindications for use of the drug, Drug dose, route of administration and duration are correct, Education of patient on the drug

1Caribbean School of Sport Sciences, University of Technology, Jamaica, Kingston, Jamaica
2School of Pharmacy, University of Technology, Jamaica, Kingston, Jamaica

Corresponding author:
Donna-Marie Wynter-Adams, University of Technology, Jamaica, 237 Old Hope Road, Kingston 6, St. Andrew, Jamaica.
Email: dwadams@utech.edu.jm
prescribed, and follow-through with patient adherence to treatment as prescribed.

RUM is an essential element in achieving quality of health care for patients and the community. Implementation of RUM practices can improve resource allocation to minimize health costs. With RUM, prescribing patterns will be more predictable, forecasting becomes easier and more accurate, thus making quantification, procurement, and budgeting more reliable. WHO reported that irrational use of medicines is more prevalent in developing and transitional countries, with its occurrence manifesting as irrational use of antibiotics, greater polypharmacy, short consultation, and dispensing times, compared to developed countries. Despite these occurrences, there was almost 100% generic prescribing, a desirable prescribing indicator. Irrational use of medicines is a global problem, which occurs because of incorrect prescribing, dispensing, inappropriate sale of medication, and poor patient adherence to the drug prescribed. This traverses many extremes, from failure to prescribe in accordance with clinical guidelines, to the practice of polypharmacy, where too many medicines are prescribed per patient.

The implications of irrational use of medicine faced by Jamaica and other developing countries, are compounded by increased health expenditures from the rise in chronic NCDs, which are recognized as a global problem with high levels of mortality and morbidity. In Jamaica, the national health and lifestyle survey reported a general increase in the prevalence of NCDs with hypertension increasing from 25.2% in 2007–8 to 31.5% in 2017–18 and diabetes from 7.8% in 2007–8 to 10% in 2017–18. This is cause for national concern as the country is a small developing state with limited economic resources. It was projected that the global disease burden of NCDs, would increase, resulting in the WHO framing the reduction in the prevalence of NCDs as a vital economic investment. The United Nations also raised the importance of reducing the prevalence of NCDs by including its reduction as one of the 2030 Sustainable Development Goals.

The increased prevalence of chronic NCDs as reported in the health and lifestyle survey in Jamaica and a contracting economy, further accelerated by the Covid-19 pandemic, warrants an evaluation of rational use of medicines and drug use compliance with therapeutic guidelines. This study is the first rational use of medicine documented for Jamaica and is novel as it incorporates alignment of recommended therapeutic guidelines as part of RUM. Another value of this study is the identification of the chronic NCDs mostly associated with irrational use of medicines in Jamaica.

As such, the objectives of this study was to assess the rational use of medicines in chronic NCDs using the WHO core indicators, to evaluate the alignment of the use of the drugs with therapeutic recommendations from local and international organizations and propose strategies for adherence to RUM best practices.

**Design and methods**

**Study design**

A quantitative retrospective cross-sectional design was used to evaluate RUM based on WHO core prescribing and facility indicators. Prescribing indicators were identified from reviews of prescriptions filled at a not-for-profit public access pharmacy between January and July 2019. A period prior to the COVID-19 pandemic was chosen, as regular clinic operations were disrupted due to the effects of the pandemic. Consecutive non-random sampling of prescriptions filled during the period under review was conducted until the sample size was achieved. The primary outcome was assessment of prescribing indicators which included, number of medicines prescribed per patient, drugs prescribed by generic name, prescribed drugs on the national formulary of vital, essential, necessary (VEN) drug list, types of drugs prescribed, quantity of drugs prescribed, noting dose and frequency, and number of drugs dispensed. The secondary outcome was evaluation of alignment of treatment to the recommended therapeutic guidelines. Key definitions and calculations that were used in protocol are as recommended in WHO guidelines.

Inclusion Criteria: Outpatient prescriptions of adult patients with at least one drug used for chronic non-communicable diseases such as cardiovascular diseases, diabetes, cancers, chronic obstructive pulmonary disease, and asthma with or without other drugs were included in this study.

Exclusion criteria: Prescriptions that did not include treatment of chronic non-communicable diseases and pediatric prescriptions were excluded from the study.

**Setting**

This facility was chosen because it patterns the government pharmacy system and makes available to patients, affordable drugs on the government vital, essential, and necessary (VEN) drugs list, as well as other drugs purchased under tender and outside of tender. The Jamaican VEN list is equivalent in function to the WHO Essential Medicines List to guide the use of drugs in the public sector. Also, this facility receives prescriptions throughout the corporate area, and can provide information on different prescribing patterns and RUM by primary and secondary care physicians.

**Participants**

Prescriptions of adult patients containing at least one drug used during the study period for the following chronic
non-communicable diseases: cardiovascular diseases, diabetes mellitus, cancers, chronic obstructive pulmonary disease (COPD), and asthma, were extracted from the physical prescription database for study inclusion. The sample size was determined according to the WHO guidelines for investigating RUM in facilities. However, based on the number of prescriptions filled by the chosen facility, and accounting for missing information on the prescriptions, a higher minimum sample size of 500 was used.

**Statistical analysis**

Data was analyzed using the Statistical Package for the Social Sciences (SPSS) software, version 22. Descriptive data were expressed as frequencies and medians and interquartile ranges. Associations were determined using chi-squared tests and correlations using Pearson’s correlation. Median number of drugs was compared using the Mann-Whitney U test. For all analyses conducted, significance was determined at \( p < 0.05 \).

**Results**

A total of 571 prescriptions were reviewed for analysis with patient demographics summarized in Table 1. The mean age of patients at the clinic pharmacy was 69 years, ranging from age 15 to 98 years (Table 1) with majority of the patients being elderly (\( \geq 65 \) years).

Most of the prescriptions were written by primary care physicians (94.7%). Of the chronic non-communicable diseases identified for study inclusion, the prescriptions were mainly written for hypertension and other NCDs as shown in Table 1. Most participants had a combination of chronic NCDs (56.6%), with hypertension and diabetes mellitus being the most prevalent comorbidities (\( n = 221, 68.4\% \)). This combination was further complicated by dyslipidemia in a total of 126 patients (39.0%). There were 3.9% of prescription encounters with antibiotics.

Results of the analysis of WHO prescribing indicators (Table 2) showed that whilst a few prescriptions had up to 11 drugs, the median number of drugs per prescription was 5. Majority of the drugs prescribed were dispensed, with a median of 3 drugs dispensed per script/patient. Polypharmacy (\( \geq 5 \) drugs) was noted on 3.9% of prescriptions, with most of the drugs prescribed being on the VEN list. The drugs were primarily written by the generic name.

Most of the drugs prescribed were dispensed as written with the reasons the drugs were not dispensed as written summarized in Table 2. Drug strength was missing for 27.0% of key drugs used in the management of the chronic NCDs assessed. These drugs include anti-asthmatic drugs (e.g. salbutamol and montelukast), combination drugs such as amiloride/hydrochlorothiazide, perindopril/indapamide, and one antibiotic, azithromycin.

| Prescription data | Prescription review (\( n = 571 \)) |
|-------------------|----------------------------------|
| Number of prescriptions reviewed, \( n \) | 571 |
| Gender, \( n \) (%) | Male 156 (27.3) | Female 360 (63.1) | Unavailable 55 (9.6) |
| Age in years, mean ± SD | 68.9 ± 13.1 (min 15, max 98) |
| Available, \( n \) (%) | 329 (57.5) |
| Missing, \( n \) (%) | 242 (42.4) |
| Age groups, years (\( n = 329 \)) | \( \leq 30 \) 5 (1.5) | 31–40 8 (2.4) | 41–50 9 (2.7) | 51–60 54 (16.4) | 61–70 98 (29.8) | 71–80 95 (28.9) | 81–90 45 (13.7) | 91–100 15 (4.6) |
| Age category, (\( n = 329 \)) | \( \geq 65 \) years, \( n \) (%) | 217 (66.0) | \(< 65 \) years, \( n \) (%) | 112 (34.0) |
| Prescribing Physician’s post, \( n \) (%) | General practitioner 541 (94.7) | Consultant/specialist 30 (5.3) |
| Chronic conditions, \( n \) (%) | Hypertension 499 (87.4) | Heart failure 49 (8.6) | Dyslipidemia 129 (22.6) | Diabetes mellitus 281 (49.2) | Asthma/COPD 28 (4.9) | Breast cancer 2 (0.4) | Other 59 (10.3) |
| Antibiotic encounters\(^a\) | 22 (3.9) |
| Morbidity | Single morbidity\(^b\) 248 (43.4) | Multimorbidity\(^c\) 323 (56.6) |

COPD: chronic obstructive pulmonary disease.
\(^a\)Antibiotic encounters, prescriptions with one or more antibiotics.
\(^b\)Single morbidity, presence of only one of conditions being investigated.
\(^c\)Multimorbidity, presence of more than one of the conditions being investigated.

Treatment of the targeted chronic NCDs was assessed and results summarized in Table 3. For hypertension, the most frequently prescribed drug therapeutic classes were thiazide diuretics, mainly hydrochlorothiazide (HCTZ) and indapamide and calcium channel blockers (CCBs), specifically amiodine and nifedipine. Five percent of patients were prescribed a combined drug formulation comprising of a thiazide diuretic with either an ACE inhibitor (e.g. perindopril/indapamide), an ARB (e.g. valsartan/HCTZ), or a
For heart failure patients, the main therapeutic class was beta blockers, primarily carvedilol. The other drug classes prescribed in the treatment of heart failure are noted in Table 3.

Metformin and sulfonylurea were prescribed for the majority of patients, with gliclazide being the preferred sulfonylurea. A total of 75 patients with diabetes were prescribed a combined drug formulation consisting of a dipeptidyl peptidase-4 (DPP-4) enzyme inhibitor and metformin. All patients with dyslipidemia were treated using statins, specifically simvastatin, rosuvastatin, and atorvastatin. The two patients with breast cancer were treated using the aromatase inhibitor, anastrozole. The “other” conditions category and prescribed drug class are noted in Table 3.

The data were analyzed for association between drugs being dispensed as written and health conditions (Table 4). Drugs being dispensed as written was significantly associated with the condition being treated. A significantly higher proportion of prescriptions for diabetic medications were not dispensed as written ($\chi^2 = 40.0, p = 0.007$). This was noted mainly on prescriptions for metformin (85.6%), gliclazide (46.0%), and glibenclamide (7.1%); where a lower strength was dispensed to meet the prescribed strength of the drug. This is because the prescriptions were usually written for strengths of $\geq 1000$, 120, and 10 mg for metformin, gliclazide, and glibenclamide, respectively, but the strengths available for each, based on the VEN list are 500, 60, and 5 mg, respectively (Table 4).

A high proportion of medications for hypertension and heart failure were also not dispensed as written (71.8%). This was mainly noted on prescriptions for enalapril, losartan, HCTZ, carvedilol, and indapamide. Enalapril and losartan were mainly prescribed at 20 and 100 mg, but the strengths dispensed were usually lower at 10 and 50 mg respectively. This was the opposite for HCTZ and carvedilol, which were generally prescribed at a strength of 12.5 and $\leq 6.25$ mg respectively but dispensed at a higher strength of 25 mg each, with the intent for the tablet to be broken to meet the prescribed strength of the drug. Indapamide was generally written as the originator brand and was responsible for the majority of the cases of drugs that were dispensed as generic instead of the brand as written.

As summarized in Table 4, chi-square analysis showed that antibiotic prescriptions were significantly associated with chronic asthma ($\chi^2 = 74.9, p < 0.001$). Chi-square analysis also showed that the post of the physician managing the patient was significantly associated with elderly patients ($\geq 65$ years).

### Table 2. Frequencies and percentages of prescribing indicators in a privately funded public access clinic in Kingston, Jamaica.

| Prescription data | Statistics |
|-------------------|------------|
|                   | Prescriptions reviewed ($n = 571$) | Total drugs ($n = 2766$) |
| Prescribing information, median (IQR) | | |
| Number of drugs per prescription ($n = 2766$) | 5 (3) | 2766 |
| Number of drugs dispensed ($n = 2067$) | 3 (3) | 2067 (74.7) |
| Number of drugs not dispensed ($n = 699$) | 1 (2) | 699 (25.3) |
| Polypharmacy ($\geq 5$ drugs) | Min: 1; max: 11 | |
| Prescribed drugs | 306 (53.6) | |
| Dispensed drugs | 169 (29.6) | |
| Prescribing from VEN list | | 2670 (96.5) |
| Yes | — | |
| No | — | 96 (3.5) |
| Prescribing drug name ($n = 2766$) | | | |
| Generic, $n$ (%) | 561 (98.2) | 2119 (76.6) |
| Brand, $n$ (%) | 365 (63.9) | 647 (23.4) |
| Dispensed drugs ($n = 2067$) | | |
| Number of drugs dispensed as written, $n$ (%) | 500 (87.6) | 1308 (63.3) |
| Number of drugs not dispensed as written, $n$ (%) | 403 (70.6) | 759 (36.7) |
| Reasons for not dispensing as written ($n = 759$) | | |
| Brand dispensed instead of generic written | — | 3 (0.4) |
| Generic dispensed instead of brand written | — | 191 (25.2) |
| Shorter duration/fewer drugs dispensed | — | 135 (17.8) |
| Longer duration/more drugs dispensed | — | 30 (4.0) |
| Lower strength dispensed | — | 326 (43.0) |
| Higher strength dispensed | — | 149 (19.6) |
| Drugs with missing strengths | — | 241 (31.8) |

IQR: interquartile range; VEN: Vital, Essential, Necessary.

*aPolypharmacy, five or more drugs written on a prescription.*
There was no significant difference between physician post and number of drugs prescribed ($p = 0.324$). However, the Mann-Whitney $U$ comparison of independent samples showed that patients aged 65 years and above were prescribed a significantly higher number of drugs compared to patients below 65 years (Table 5). This was further supported by the significant and moderately positive correlation between age and number of drugs prescribed ($r = 0.24$, $p < 0.001$).

A summary of RUM indicators is provided in Table 6. Based on the prescribing indicators studied, only one was achieved (antibiotics encounter), with a second target, prescribing from the VEN (essential) drug list being 3.5% off the 100% target. All other factors were outside of the WHO optimal value.

### Discussion

The aims of this study were to assess RUM for chronic NCDs using WHO prescribing indicators; evaluate the alignment of the use of the drugs with therapeutic recommendations from local and international organizations and propose strategies for adherence to RUM practices. Comparable to other studies, there were more female patients than males, with about one quarter of the prescription encounters being for male patients.\(^{12,13}\) Most of the patients in the study population were elderly ($\geq 65$ years) with only 34% being in the working age group. This may be related to selection of patients with NCDs as other studies have found greater prevalence of NCDs in the older/retired population ($\geq 65$ years).\(^ {14,15}\)

Most of the prescribed drugs were dispensed (74.7%), which is similar to that seen in other low to middle income countries.\(^ {5,16}\) This alludes to general compliance with prescribed drugs, but the non-adherence to WHO rational use of medicines 100% prescription filling standard may be due to patient non-compliance because of increased pill burden present in patients with multimorbidity.\(^ {17-19}\) The 76.6% generic prescribing was below the 100% standard for RUM, however, the drugs prescribed by brand were primarily for drugs on the VEN list or drugs still under patent with no generic option available. Whilst this lower rate of generic prescribing does not adhere to RUM, the local government policy allows for generic substitution of brand drugs written on prescriptions, if a generic is available.\(^ {20}\)

There was 96.5% prescribing compliance to the VEN list and this compares well with the 100% adherence recommended by WHO.\(^ {11}\) This is also comparable to results from studies in other low to middle income countries.\(^ {4,5}\) Encouragingly, antibiotic encounters for this patient population were low (3.9%) and well within the RUM guidelines of less than 30%.\(^ {11}\) Overuse of antibiotics has been linked to an increase in antimicrobial resistance and has the potential to cause widespread suffering and mortality.\(^ {21}\)

Majority of the drugs prescribed were dispensed as written, with those not dispensed as written being mainly due to strength modifications. Drug strength modification is the main alteration reported for prescriptions of older

### Table 3. Classes of medications prescribed for chronic NCDs at a privately funded public access clinic pharmacy in Kingston, Jamaica.

| Drug classes ($n = 571$) | Frequency, $n$ (%) |
|--------------------------|--------------------|
| Hypertension ($n = 499$) |                     |
| ACE inhibitor            | 208 (41.7)         |
| ARB                      | 198 (39.7)         |
| Beta blocker             | 60 (12.0)          |
| CCB                      | 317 (63.5)         |
| Thiazide diuretic        | 320 (64.1)         |
| Combined drug*           | 25 (5.0)           |
| Heart failure ($n = 49$) |                     |
| ACE inhibitor            | 16 (32.7)          |
| ARB                      | 11 (22.4)          |
| Beta blocker             | 34 (69.4)          |
| Cardiac glycoside        | 3 (6.1)            |
| Loop diuretic            | 10 (20.4)          |
| Spironolactone           | 4 (8.2)            |
| Vasodilator              | 7 (14.3)           |
| Dyslipidemia ($n = 129$) |                     |
| Statin                   | 129 (100.0)        |
| Diabetes mellitus ($n = 281$) |                   |
| Alpha-glucosidase inhibitor | 13 (4.6)       |
| Biguanide                | 275 (97.9)         |
| Insulin                  | 65 (23.1)          |
| Sulfonylurea             | 169 (60.1)         |
| Thiazolidinedione        | 60 (21.4)          |
| Combined drug*           | 75 (26.7)          |
| Asthma/COPD ($n = 28$)   |                     |
| Beta-2 agonist           | 27 (96.4)          |
| Montelukast              | 5 (17.9)           |
| Salmeterol + Fluticasone propionate | 1 (3.6)   |
| Prednisolone             | 1 (3.6)            |
| Breast cancer ($n = 2$)  |                     |
| Aromatase inhibitor      | 2 (100.0)          |
| Other ($n = 59$)         |                     |
| Antiplatelet             | 44 (74.6)          |
| Anti-inflammatory/analgesic | 30 (50.8)   |
| Anti-allergy             | 13 (22.0)          |
| Antifungal               | 9 (15.3)           |
| BPH                      | 25 (42.4)          |
| PPI                      | 10 (17.0)          |
| Thyroid                  | 2 (3.4)            |
| Vascular                 | 20 (33.9)          |
| Vitamins/minerals        | 26 (44.1)          |

ACE: angiotensin converting enzyme; ARB: angiotensin receptor blocker; BPH: benign prostatic hyperplasia; CCB: calcium channel blocker; PPI: proton pump inhibitor.

*Combined drug for hypertension: Thiazide + ACE inhibitor, or ARB, or CCB.

*Combined drug for diabetes mellitus: dipeptidyl peptidase-4 (DPP-4) enzyme inhibitor + Metformin.
Table 4. Chi-square analysis of associations between health conditions, drugs dispensed as written, and antibiotics prescribed.

| Prescription data | Yes (n=500) | No (n=71) | Chi-square analysis ($\chi^2$, p) |
|-------------------|-------------|-----------|---------------------------------|
| Conditions        |             |           |                                 |
| Hypertension      | 448 (89.6)  | 51 (71.8) | 40.0, 0.007*                     |
| Heart failure     | 46 (9.2)    | 3 (4.2)   |                                 |
| Dyslipidemia      | 119 (23.8)  | 10 (14.1) |                                 |
| Diabetes mellitus | 242 (48.4)  | 39 (54.9) |                                 |
| Asthma/COPD       | 27 (5.4)    | 1 (1.4)   |                                 |
| Cancer            | 1 (0.2)     | 1 (1.4)   |                                 |
| Antibiotic        | 19 (3.8)    | 3 (4.2)   |                                 |

| Antibiotic prescribed, n (%) |
|-----------------------------|
| Yes (n=22)                  | No (n=549)     |
| Hypertension                | 16 (72.7)      | 483 (88.0) |
| Heart failure               | 0              | 49 (8.9)   |
| Dyslipidemia                | 0              | 129 (23.5) |
| Diabetes mellitus           | 8 (36.4)       | 273 (49.7) |
| Asthma/COPD                 | 6 (27.3)       | 22 (4.0)   |
| Cancer                      | 0              | 2 (0.4)    |

Prescribing Physician’s post, n (%)

|            | GP (n=316) | Consultant (n=13) |
|------------|------------|-------------------|
| ≥65 years, n (%) | 204 (64.6) | 13 (100.0) |
| <65 years, n (%) | 112 (35.4) | 0 | 7.0, 0.008* |

COPD: chronic obstructive pulmonary disease; GP: general practitioner.
*Significant associations at p < 0.05.

Table 5. Comparisons of the number of drugs prescribed between categories of age and Physician’s post.

| Prescription data (n=571) | Number of drugs prescribed |
|---------------------------|-----------------------------|
|                           | Median (IQR) | Mann-Whitney U test p |
| Age category (n=329)      |               |                       |
| ≥65 years (n=217)         | 6 (3)         | <0.001*                |
| <65 years (n=112)         | 4 (3)         |                       |
| Pearson’s correlation (r, p) | 0.24, <0.001* |           |
| Prescribing Physician’s post |         |                       |
| General Practitioner (n=541) | 5 (3) | 0.324               |
| Consultant (n=30)         | 6 (2)         |                       |

IQR: interquartile range; r: Pearson’s coefficient for the correlation between age and number of drugs prescribed.
*Significant associations at p < 0.05.

Diabetes drugs were significantly associated with not being dispensed as written. This was noted with metformin and gliclazide which were the most frequently prescribed diabetic drugs. These drugs were mostly prescribed at higher strengths than available on the VEN list. This suggests that the disease severity was generally high in the study population, requiring higher doses. In some cases, higher drug strengths were available but the dose form on the VEN list was lower, requiring doubling of the available dose strength to equate to the prescribed strength. A similar pattern was seen for treatment of hypertension. Most studies reported irrational use in broad treatment categories but did not indicate the drugs associated with irrational use nor describe dose modification as the reason for
irrational use.\textsuperscript{5-6,16,23} This practice of dose modification causes higher pill burden and has implications for patients’ adherence to treatment due to confusion, frustration, and doubting the effectiveness of treatment caused by the number of pills prescribed.\textsuperscript{17,24} These factors can lead to poor compliance to drug treatment and affect quality of life from increased morbidity and mortality in patients with NCDs.\textsuperscript{25}

Non-communicable diseases can have tremendous impact on a country’s economy, with the impact in low to middle income countries being three times that of high income countries\textsuperscript{14,26} and is the cause of death in 30–69 years olds in these countries.\textsuperscript{15,27} Cardiovascular diseases, specifically hypertension, accounted for the majority of the NCDs in this study, with more than half of the patients having multimorbidity, defined as having more than one comorbid condition.\textsuperscript{28} Multimorbidity is linked to age and also has attendant issues such as high polypharmacy with increased risk of adverse drug events, poor patient compliance, and added healthcare costs.\textsuperscript{15,18,19} In this study the prevalence of multimorbidity was high (56.6%), as was the degree of polypharmacy (53.6%), which was above the optimal number of drugs (≤5) recommended by WHO for RUM.\textsuperscript{29} This was expected in the older study population and comparable to other reports on the average drug use in chronic NCDs in low to middle income countries.\textsuperscript{19,30} NCDs with its higher drug usage was noted as a major public health burden by the Ministry of Health and Wellness in Jamaica, which added to the country’s cost of care.\textsuperscript{14,31} The high prevalence of encounters/prescriptions for hypertension drugs was expected since Jamaica has a 30% prevalence of hypertension in the general population.\textsuperscript{10} The Jamaica Health and Lifestyle Survey (JHLSIII) reported that adherence to lifestyle changes to assist in the management of NCDs like hypertension and diabetes may be low, as 70% of the population did not have adequate resources to consume sufficient or nutritious foods and only 16% engaged in moderate physical activity as recommended by WHO.\textsuperscript{10} This therefore means that the modest reductions in disease severity due to lifestyle intervention is unlikely to be met, leading to greater dependence on drug therapy. The high level of prescriptions from general practitioners aligns with international consensus that multimorbidity is best treated in a primary care setting, which allows for the holistic approach to patient treatment rather than symptomatic management by different specialists.\textsuperscript{32,33}

In accordance with local and international guidelines, the majority of patients with diabetes were treated using metformin and patients with cardiovascular diseases were treated with either a thiazide diuretic, calcium channel blocker (CCB), or angiotensin modifying drug (ACE inhibitor or ARB). This is in alignment with treatment guidelines recommended for Black populations.\textsuperscript{34,35} Whilst this is not a direct RUM indicator, it speaks to adherence to therapeutic guidelines for effective management of patients, which is a part of rational use of medicines. Additionally, the high use of angiotensin modifying drugs may be related to the high comorbid presence of diabetes, as ACE inhibitors are associated with cardiovascular benefits, delay in new onset diabetes and renal protection in at risk patients.\textsuperscript{36-38} A combined drug formulation is generally associated with better compliance from reduced pill burden and could be used with great efficacy in a multimorbidity population.\textsuperscript{39} Despite this, only 5% of patients with hypertension and 26.7% of patients with hyperglycemia were treated with a combined drug formulation.

Overall, the use of drugs in this clinic setting in Jamaica was not rational based on WHO standards, as four of the prescribing factors to ascertain rational use were not met. However, prescribing based on the VEN (essential) drug list was not significantly below the WHO standard. Also, prescribing using the generic name of the drug, although not achieved, would be mitigated as the Generic Law in Jamaica requires that the generic drug instead of the brand can be dispensed at the pharmacy.\textsuperscript{20} A value of this study is in the evaluation of adherence to therapeutic guidelines as a part of rational use of medicines and the noting of the impact of multimorbidity on prescribing indicators. The limitations of the study include use of one site and as such the data cannot be extrapolated to the entire country. Another limitation is selection of chronic non-communicable diseases which are associated with multiple drug treatments which may affect the number of drugs prescribed per patient (prescription encounters) and hence cannot be extrapolated to the general population.\textsuperscript{18,19} The information gathered is valuable but would be better supported by data from the government pharmacy database.

Table 6. Comparison of study rational use of medicine with WHO (1985) guidelines.

| Factor                          | WHO value | Study value |
|---------------------------------|-----------|-------------|
| Average number of drugs/prescriptions | 1.6–1.8   | 5           |
| Proportion of generic prescribing (%) | 100       | 76.6        |
| Proportion of antibiotic encounters (%) | <30       | 3.9         |
| Percentage drugs dispensed (%)   | 100       | 74.7        |
| Percentage drugs prescribed from VEN list (%) | 100       | 96.5        |

VEN: vital, essential, necessary; WHO: World Health Organization.
The study recommendations are that patient prescriptions be assessed for relevance of drugs with use of fixed dose combination formulations to reduce pill burden and polypharmacy. The VEN list should carry all forms of the drug with procurement based on drug use patterns, so that the frequently used strengths are available to reduce the need to double pills or cut pills to meet the dose requirement. Despite the Generic Drug Law, physicians should be encouraged to prescribe by generic name, as generic drugs may become available for brand name drugs without their knowledge. The notable difference between percentage dispensed versus drugs prescribed indicates a need for more patient education on the benefits of adherence to treatment for improved treatment outcomes.

Conclusion

In conclusion, rational use of medicines was low in this setting, with four of the five prescribing indicators being assessed for RUM not achieved. The average number of drugs per encounter/prescription being less than 1.8, all drugs prescribed by generic name, all drugs on the prescription being dispensed and only drugs on the VEN list being prescribed were outside of the WHO RUM standard. Drugs being prescribed only from the VEN (essential) drug list was slightly outside of the 100% requirement of the WHO standard. Only the number of antibiotic encounters (3.9%) achieved the RUM target of less than 30%. There was adherence of drugs prescribed with the recommendations from international and local therapeutic committees. This can be used as a proxy for rational use of medicines as the therapeutic recommendations are made for efficient management of disease states based on the efficacy and safety data to achieve best outcomes for patient management. Rational use of medicines in this setting can be improved through reduction in the number of drugs per prescription. However, multimorbidity and polypharmacy are prevalent in the older population within this clinic setting and would affect the ability to achieve the WHO standard for 1.8 drugs per prescription. In this regard, greater use of combined formulations may be employed to reduce pill burden and increase compliance. Whilst prescribing by generic name is suboptimal, majority of the prescribed drugs were on the VEN list. Physicians may not be concerned about the use of the generic or brand name as the Generic Law in Jamaica allows for generic substitution at the pharmacy.

Acknowledgements

The authors thank the members of the clinic who facilitated research at the facility.

Author contributions

DWA contributed to the design of the study, data collection, interpretation, and writing of the manuscript. PTB contributed to the statistical oversight of the study, data collection, analysis, interpretation, and writing of the manuscript. MW contributed to data collection, writing, and review of the manuscript. LB contributed to data collection, writing, and review of the manuscript. JBC contributed to data collection, writing, and revision of the manuscript. All authors have read and approved the final manuscript.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research received partial funding from the CIMLAC Network through support from PAHO/WHO.

Ethics approval and consent to participate

This study was reviewed and approved by the University of Technology, Jamaica Ethics Committee [protocol Number: 2021/09/UtechJa./773] and the Ministry of Health & Wellness South Regional Health Authority Ethics Committee and permission granted from the Foundation for International Self Help Board. Patients and/or the public were not involved in the design, conduct, reporting, or dissemination plans of this research.

Patient consent for publication

Not applicable.

Significance for public health

This study incorporates alignment of recommended therapeutic guidelines with rational use of medicines (RUM) to describe the first RUM literature for Jamaica. A value of this study is the identification of chronic non-communicable diseases that are mostly associated with irrational use of medicines, as seen by multiple drug treatments that contributes to an increased number of drugs per encounter/prescription. Of the WHO prescribing factors assessed, only the antibiotic encounter was within the RUM optimal recommendation. As such, strategies to improve adherence to RUM are highly recommended in this setting to maximize therapeutic outcomes and enhance efficient use of health resources.

ORCID iD

Donna-Marie Wynter-Adams https://orcid.org/0000-0001-5134-4928

Availability of data and materials

Data are available upon reasonable request. The datasets used and/or analyzed for the current study are only available in compliance with the Jamaica Data Protection Act.

References

1. World Health Organization. *Promoting rational use of medicines: core components*. Geneva: World Health Organization, 2002.
2. World Health Organization. The pursuit of responsible use of medicines: sharing and learning from country experiences. Geneva: World Health Organization, 2012.

3. Nunan E. Rational use of medicines in developing countries. *J Pharm Pract Res* 2017; 47(1): 6–7.

4. Mahmood A, Elnoun AA, Ali AA, et al. Evaluation of rational use of medicines (RUM) in four government hospitals in UAE. *Saudi Pharm J* 2016; 24(2): 189–196.

5. Sisay M, Mengistu G, Molla B, et al. Evaluation of rational drug use based on World Health Organization core drug use indicators in selected public hospitals of eastern Ethiopia: a cross sectional study. *BMJ Health Serv Res* 2017; 17(1): 1–9.

6. Lima MG, Álvares J, Guerra AA, et al. Indicators related to the rational use of medicines and its associated factors. *Revista de Saúde Pública* 2017; 51: 235.

7. Jamaica Health and Lifestyle Survey III (2016–2017), [Internet], https://www.moh.gov.jm/wp-content/uploads/2018/09/Jamaica-Health-and-Lifestyle-Survey-III-2016-2017.pdf (2018, accessed 12 November 2021).

8. Unwin N and Alberti KGMM. Chronic non-communicable diseases. *Ann Trop Med Parasitol* 2006; 100(5–6): 455–464.

9. Zuccala E and Horton R. Reframing the NCD agenda: a matter of justice and equity. *Lancet* 2020; 396(10256): 939–940.

10. Bennett JE, Kontis V, Mathers CD, et al.; NCD Countdown 2030 collaborators. NCD Countdown 2030: pathways to achieving sustainable development goal target 3.4. *Lancet* 2020; 396(10255): 918–934.

11. World Health Organization. How to investigate drug use in health facilities: selected drug use indicators. Geneva: World Health Organization, 1993.

12. Galdas PM, Cheater F and Marshall P. Men and health help-seeking behaviour: literature review. *J Adv Nurs* 2005; 49(6): 616–623.

13. Hunt K, Adamson J and Galdas P. Gender and help-seeking: towards gender-comparative studies. In: Kuhlmann E and Amandale E (eds) *The Palgrave handbook of gender and healthcare*. London: Palgrave Macmillan, 2010, pp.207–221.

14. Bloom DE, Chen S and McGovern ME. The economic burden of noncommunicable diseases and mental health conditions: results for Costa Rica, Jamaica, and Peru. *Rev Panam Salud Publica* 2018; 42: e18.

15. Bourne PA, Francis C, Sharpe-Pryce C, et al. Epidemic of non-communicable diseases in Jamaica: monsters awoken from lifestyle practices. *Open Access Libr J* 2014; 1: e282.

16. Mamo DB and Alemu BK. Rational drug-use evaluation based on World Health Organization core drug-use indicators in a tertiary referral hospital, Northeast Ethiopia: a cross-sectional study. *Drug Healthc Patient Saf* 2020; 12: 15–21.

17. Farrell B, French Merkley V and Ingar N. Reducing pill burden and helping with medication awareness to improve adherence. *Can Pharm J* 2013; 146(5): 262–269.

18. van den Akker M, Buntinx F, Metsemakers JF, et al. Multimorbidity in general practice: prevalence, incidence and determinants of co-occurring chronic and recurrent diseases. *J Clin Epidemiol* 1998; 51(5): 367–375.

19. Man MS, Chaplin K, Mann C, et al. Improving the management of multimorbidity in general practice: protocol of a cluster randomised controlled trial (The 3D study). *BMJ Open* 2016; 6: e011261.

20. Gossell-Williams M. Generic substitutions: a 2005 survey of the acceptance and perceptions of physicians in Jamaica. *West Indian Med J* 2007; 56(5): 458–463.

21. World Health Organization. WHO report on surveillance of antibiotic consumption: 2016-2018 early implementation, [Internet], https://www.who.int/publications/i/item/who-report-on-surveillance-of-antibiotic-consumption (2019, accessed 17 February 2012).

22. von Buedingen F, Hammer MS, Meid AD, et al. Changes in prescribed medicines in older patients with multimorbidity and polypharmacy in general practice. *BMC Fam Pract* 2018; 19(1): 131.

23. Deslandes P, Blowers H, Haines K, et al. Medicines prescribed by non-medical independent prescribers in primary care in Wales: a 10-year longitudinal study April 2011-March 2021. *BMJ Open* 2022; 12: e059204.

24. Hauber AB, Han S, Yang JC, et al. Effect of pill burden on dosing preferences, willingness to pay and likely adherence among patients with type 2 diabetes. *Patient Prefer Adherence* 2013; 7: 937–949.

25. Chao S, Carpio C and de Geyndt W. Non-communicable diseases in Jamaica: moving from prescription to prevention. *en breve*, 171. Washington, DC: World Bank. © World Bank, 2011. https://openknowledge.worldbank.org/handle/10986/10078 (accessed 6 June 2022). License: CC BY 3.0 IGO.

26. Boutayeb A, Boutayeb S and Boutayeb W. Multi-morbidity of non communicable diseases and equity in WHO Eastern Mediterranean countries. *Int J Equity Health* 2013; 12(1): 60.

27. Pan American Health Organization. Rational use of medicines and other health technologies, [Internet], https://www.paho.org/en/topics/rational-use-medicines-and-other-health-technologies (n.d., accessed 17 February 2021).

28. World Health Organization (WHO). *Multimorbidity, technical series on safer primary care*. Geneva: World Health Organization, 2016. License: CC BY-NC-SA 3.0 IGO.

29. World Health Organization. *Thirty-ninth World Health Assembly*. Geneva: World Health Organization, 1986.

30. Riaz H, Godman B, Bashir S, et al. Evaluation of drug use indicators for non-communicable diseases in Pakistan. *Interactions* 2016; 18: 19.

31. Ministry of Health and Wellness. The non-communicable disease and injury prevention unit, [Internet], https://www.moh.gov.jm/programmes-policies/chronic-non-communicable-diseases (n.d., accessed 6 June 2022).

32. US Department of Health and Human Services. *Multiple chronic conditions - a strategic framework: optimum health and quality of life for individuals with multiple chronic conditions*. Washington, DC: US Department of Health and Human Services, 2010, p.2.

33. Kernick D, Chew-Graham CA and O’Flynn N. Clinical assessment and management of multimorbidity: NICE guideline. *Br J Gen Pract* 2017; 67(658): 235–236.

34. Whelton PK, Carey RM, Aronow WS, et al. ACC/AHA/ABC/ACPM/AGS/AAPA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *J Am Coll Cardiol* 2018; 71(19): e127–e248.
35. Williams B, Mancia G, Spiering W, et al. ESC/ESH guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). *Eur Heart J* 2018; 39(33): 3021–3104.

36. Messerli FH, Bangalore S, Bavishi C, et al. Angiotensin-converting enzyme inhibitors in hypertension: to use or not to use? *J Am Coll Cardiol* 2018; 71(13): 1474–1482.

37. Materson BJ and Preston RA. Angiotensin-converting enzyme inhibitors in hypertension: a dozen years of experience. *Arch Intern Med* 1994; 154(5): 513–523.

38. Solski LV and Longyhore DS. Prevention of type 2 diabetes mellitus with angiotensin-converting-enzyme inhibitors. *Am J Health Syst Pharm* 2008; 65(10): 935–940.

39. Webster R. Fixed-dose combination medications for non-communicable diseases. *Heart* 2019; 105(3): 176–177.